News | February 10, 2026
GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The revenues this quarter are in line with the outlook we envisaged for the year
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children
The new service delivers end-to-end support, managing every stage of an epigenomics project
The approved Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference drug and will be manufactured at Indoco’s facility in Verna Industrial Area, Goa
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Subscribe To Our Newsletter & Stay Updated
